‘Biotech is the ultimate impact investment’ — family offices can’t get enough of it
The Lauber family built its wealth in real estate, and that’s where it stayed for decades. But, lately, some of the family money has a buzzy new destination: biotech. “I’m kind of like a hypochondriac,” says Robin Lauber, the third-generation heir who is diversifying the Swiss family’s wealth, mainly into companies working in cutting-edge biology. Lauber, 30, is particularly interested in longevity medicine, a nascent strand of research that aims to slow down the ageing process. Continue Reading..
|